Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: The placebo-controlled SEDUCE study

Annals of the Rheumatic Diseases

Volumn 75, Issue 6, 2016, Pages 1009-1015

  Hachulla, Eric ^a   Hatron, Pierre Yves ^a   Carpentier, Patrick ^b   Agard, Christian ^c   Chatelus, Emmanuel ^d   Jego, Patrick ^e   Mouthon, Luc ^f   Queyrel, Viviane ^g   Fauchais, Anne Laure ^h   Michon Pasturel, Ulrique ⁱ   Jaussaud, Roland ^j   Mathian, Alexis ^k   Granel, Brigitte ^l   Diot, Elisabeth ^m   Farge Bancel, Dominique ⁿ   Mekinian, Arsène ^o   Avouac, Jérôme ^p   Desmurs Clavel, Hélène ^q   Clerson, Pierre ^r  

^a UNIV LILLE   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c HÔTEL DIEU   (France)

^d HÔPITAL DE HAUTEPIERRE   (France)

^e RENNES UNIVERSITY HOSPITAL   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^h DUPUYTREN UNIVERSITY HOSPITAL   (France)

ⁱ SAINT JOSEPH HOSPITAL   (France)

^j SERVICE DE DERMATOLOGIE   (France)

^k PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^l AIX MARSEILLE UNIVERSITY   (France)

^m CHU BRETONNEAU   (France)

ⁿ SAINT LOUIS HOSPITAL   (France)

^o HÔPITAL SAINT ANTOINE   (France)

^p université Paris Cité   (France)

^q EDOUARD HERRIOT HOSPITAL   (France)

^r Orgamétrie Biostatistiques   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; PLACEBO; SILDENAFIL; VASODILATOR AGENT;

ADULT; ARTICLE; COCHIN HAND FUNCTION SCORE; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG WITHDRAWAL; FACE EDEMA; FAINTNESS; FEMALE; FINGER ULCER; FRANCE; FUNCTIONAL ASSESSMENT; GANGRENE; HAND FUNCTION; HEADACHE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INTENTION TO TREAT ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN INTENSITY; PARALLEL DESIGN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RAYNAUD PHENOMENON; SKIN INFECTION; SYSTEMIC SCLEROSIS; ULCER HEALING; COMPLICATION; FINGER; ISCHEMIA; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SKIN ULCER; TIME FACTOR; TREATMENT OUTCOME; VASCULARIZATION;

ADULT; DOUBLE-BLIND METHOD; FEMALE; FINGERS; HUMANS; INTENTION TO TREAT ANALYSIS; ISCHEMIA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; SILDENAFIL CITRATE; SKIN ULCER; TIME FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84931332701     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-207001     Document Type: Article

References (23)

1. Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002;81:139-53.
2. Hachulla E, Clerson P, Launay D, et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol 2007;34:2423-30.
3. Tiev KP, Diot E, Clerson P, et al. Clinical features of scleroderma patients with or without prior or current ischemic digital ulcers: post-hoc analysis of a nationwide multicenter cohort (ItinerAIR-Sclerodermie). J Rheumatol 2009;36:1470-6.
4. Nihtyanova SI, Brough GM, Black CM, et al. Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2008;67:120-3.
5. Mouthon L, Carpentier PH, Lok C, et al. Ischemic digital ulcers affect hand disability and pain in systemic sclerosis. J Rheumatol 2014;41:1317-23.
6. Tingey T, Shu J, Smuczek J, et al. Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res (Hoboken) 2013;65:1460-71.
7. Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93.
8. Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011;70:32-8.
9. Fries R, Shariat K, von Wilmowsky H, et al. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005;112:2980-5.
10. Farsaie S, Khalili H, Karimzadeh I, et al. An old drug for a new application: potential benefits of sildenafil in wound healing. J Pharm Pharm Sci 2012;15:483-98.
11. Brueckner CS, Becker MO, Kroencke T, et al. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis 2010;69:1475-8.
12. Della Rossa A, Doveri M, D'Ascanio A, et al. Oral sildenafil in skin ulcers secondary to systemic sclerosis. Scand J Rheumatol 2011;40:323-5.
13. Shenoy PD, Kumar S, Jha LK, et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford) 2010;49:2420-8.
14. American Rheumatism Association Scleroderma Criteria Subcommittee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
15. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
16. Rannou F, Poiraudeau S, Berezne A, et al. Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey. Arthritis Rheum 2007;57:94-102.
17. Vaida F, Xu R. Proportional hazards model with random effects. Stat Med 2000;19:3309-24.
18. Lin DY. Cox regression analysis of multivariate failure time data: the marginal approach. Stat Med 1994;13:2233-47.
19. Spiekerman CF, Lin DY. Marginal regression models for multivariate failure time data. J Am Stat Assoc 1998;93:1164-75.
20. Herrick AL, van den Hoogen F, Gabrielli A, et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum 2011;63:775-82.
21. Schiopu E, Hsu VM, Impens AJ, et al. Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. J Rheumatol 2009;36:2264-8.
22. Rademaker M, Cooke ED, Almond NE, et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ 1989;298:561-4.
23. Galiè N, Ghofrani HA, Torbicki A, et al., Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57.